Richards Emily D, Dutch Rachel S, Burmas Nathaniel C, Davis Jennifer L, Lin Zhoumeng, Clapham Maaike O, Wetzlich Scott E, Tell Lisa A
Food Animal Residue Avoidance and Depletion Program, Davis, CA, United States.
Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.
Front Vet Sci. 2022 Mar 3;9:826367. doi: 10.3389/fvets.2022.826367. eCollection 2022.
Meloxicam is commonly prescribed for treating chickens in backyard or small commercial operations despite a paucity of scientific data establishing tissue withdrawal interval recommendations following extra-label drug use (ELDU). Historically, ELDU withdrawal intervals (WDIs) following meloxicam administration to chickens have been based on the time when meloxicam concentrations fall below detectable concentrations in plasma and egg samples. To date, no studies have addressed tissue residues. ELDU WDIs are commonly calculated using terminal elimination half-lives derived from pharmacokinetic studies. This study estimated pharmacokinetic parameters for laying hens following meloxicam administration and compared ELDU WDIs calculated using tissue terminal elimination half-lives vs. those calculated using FDA tolerance and EMA's maximum regulatory limit statistical methods, respectively. In addition, ELDU WDIs were calculated using plasma meloxicam concentrations from live birds to determine if plasma data could be used as a proxy for estimating tissue WDIs. Healthy domestic hens were administered meloxicam at 1 mg/kg intravenous (IV) once, 1 mg/kg orally (PO) once daily for eight doses or 1 mg/kg PO twice daily for 20 doses. Analytical method validation was performed and meloxicam concentrations were quantified using high-performance liquid chromatography. In general, the terminal elimination technique resulted in the longest ELDU WDIs, followed by the FDA tolerance and then EMA's maximum residue limit methods. The longest ELDU WDIs were 72, 96, and 384 (or 120 excluding fat) h for the IV, PO once daily for eight doses, and PO twice daily for 20 doses, respectively. Plasma data are a possible dataset for estimating a baseline for tissue ELDU WDI estimations when tissue data are not available for chickens treated with meloxicam. Finally, pharmacokinetic parameters were similar in laying hens to those published for other avian species.
尽管缺乏科学数据来确定超说明书用药(ELDU)后组织停药间隔的建议,但美洛昔康仍常用于后院或小型商业养殖中鸡的治疗。从历史上看,给鸡使用美洛昔康后的ELDU停药间隔(WDIs)是基于美洛昔康浓度在血浆和蛋样中降至可检测浓度以下的时间。迄今为止,尚无研究涉及组织残留。ELDU WDIs通常使用药代动力学研究得出的终末消除半衰期来计算。本研究估计了美洛昔康给药后蛋鸡的药代动力学参数,并比较了分别使用组织终末消除半衰期与使用FDA耐受性和EMA最大监管限量统计方法计算的ELDU WDIs。此外,使用活禽的血浆美洛昔康浓度计算ELDU WDIs,以确定血浆数据是否可作为估计组织WDIs的替代指标。对健康的家养母鸡静脉注射(IV)一次1 mg/kg美洛昔康,或口服(PO)一次1 mg/kg,每日一次,共八剂,或口服1 mg/kg,每日两次,共20剂。进行了分析方法验证,并使用高效液相色谱法定量美洛昔康浓度。一般来说,终末消除技术得出的ELDU WDIs最长,其次是FDA耐受性方法,然后是EMA最大残留限量方法。静脉注射、口服一次每日八剂、口服两次每日20剂的最长ELDU WDIs分别为72、96和384(或不包括脂肪为120)小时。当无法获得美洛昔康治疗鸡的组织数据时,血浆数据可能是用于估计组织ELDU WDI估计基线的数据集。最后,蛋鸡的药代动力学参数与其他禽类已发表的参数相似。